Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07371975 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms
A NA study of Gut Health, sponsored by Supplement Formulators.
- Recruiting
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT07371975: Recruiting NA study of Gut Health, sponsored by Supplement Formulators.
NCT07371975 is a NA study of Gut Health that is actively recruiting participants, run by Supplement Formulators. The registered enrollment target is 124 participants, above the 49-participant average among 9 other Gut Health trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07371975, a NA study of Gut Health, is actively recruiting participants, sponsored by Supplement Formulators.
- RECRUITING
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the efficacy of a butyrate/polyphenol formulation on modulation of the gut microbiome and gastrointestinal symptoms using questionnaires in individuals with self-reported gastrointestinal discomfort.
Primary Outcome
Change in the Gastrointestinal Symptom Rating Scale-IBS from baseline. The responses to the questions range from no discomfort at all to very severe discomfort which would indicate a worse outcome
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Butyrate + Polyphenol Formulation
Study Locations (1)
Florida
- Life Extension Clinical Research, Inc. - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-07-30 |
| Phase | NA |
What NCT07371975 shows while recruiting
NCT07371975 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 49-participant average among 9 other Gut Health trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Gut Health appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07371975 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07371975 about?
NCT07371975 is a clinical study titled "A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms". The purpose of the study is to evaluate the efficacy of a butyrate/polyphenol formulation on modulation of the gut microbiome and gastrointestinal symptoms using questionnaires in individuals with self-reported gastrointestinal discomfort.
What is the current status of trial NCT07371975?
This trial is currently recruiting. It is a NA study. The enrollment target is 124 participants. The study started on 2025-10-16. Estimated completion is 2026-07-30.
What conditions does trial NCT07371975 study?
This clinical trial studies the following conditions: Gut Health.
What interventions are being tested in trial NCT07371975?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Butyrate + Polyphenol Formulation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07371975?
This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07371975 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gut Health
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07371975's enrollment target sits among peer trials
124 1st of 9 higher than 9 of 9 other Gut Health trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gut Health trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes
RECRUITING · NA
-
An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System
RECRUITING · NA
-
The Effect Cranberry-Based Products on the Female Microbiome
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
-
Effects of Effera Human Lactoferrin at One Dose Compared to Placebo on Gut Permeability
RECRUITING · NA
-
Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI